Biotech firms Arrowhead and Sarepta form a $500M+ deal targeting rare genetic diseases.

Arrowhead Pharmaceuticals and Sarepta Therapeutics have entered a significant collaboration focused on rare genetic diseases affecting muscles, the central nervous system, and lungs. Under the agreement, Sarepta pays Arrowhead $500 million upfront and invests $325 million in equity, with potential royalties and milestone payments up to $10 billion. The deal includes four clinical-stage drugs and allows Sarepta to propose up to six new research targets over five years. Arrowhead's stock surged on the news.

November 26, 2024
5 Articles